P

P. < .0001New ASCUS+ associated with HPV-16 (instances = 536, noncases = 7302)aSeronegative484617224 Mouse monoclonal to Alkaline Phosphatase 3471.991.001.00Seropositive52113042511.220.62 (.46C.82)0.60 (.45C.80).0006Seropositive, quartiles, EU/mL?8C122030911761.700.86 (.55C1.34)0.91 (.58C1.42).67?>12C21132539591.360.68 (.39C1.18)0.66 (.38C1.14).14?>21C591128110491.050.53 (.29C.96)0.51 (.28C.93).028?>59C2805828710670.750.38 (.19C.76)0.33 (.16C.67).0022value for linear tendency < .0001New CIN1+ associated with HPV-16 (instances = 177, noncases = 7661)aSeronegative157649924 9390.631.001.00Seropositive20116243260.460.73 (.46C1.17)0.70 (.44C1.14).15Seropositive, quartiles, EU/mL?8C121031912040.831.32 (.70C2.50)1.38 (.72C2.64).33?>12C2152619730.510.82 (.34C1.99)0.78 (.32C1.90).58?>21C59428810630.380.60 (.22C1.61)0.56 (.21C1.52).26?>59C2805129410860.090.15 (.02C1.05)0.13 (.02C.90).039value for linear tendency = .0006New CIN2+ associated with HPV-16 (instances = 121, noncases = 7717)aSeronegative109654724 9840.441.001.00Seropositive12117043390.280.63 (.35C1.15)0.62 (.34C1.15).13Seropositive, quartiles, EU/mL?8C12632312080.501.14 (.50C2.59)1.21 (.53C2.76).66?>12C2122649800.200.47 (.12C1.89)0.45 (.11C1.83).26?>21C59328910650.280.65 (.21C2.03)0.63 (.20C1.99).43?>59C2805129410860.090.21 (.03C1.51)0.19 (.03C1.38).10value for linear tendency = .018 Open in a separate window Incident infection was defined as a new detection of the HPV type at any time during the follow-up period; 6- and 12-month prolonged infection were defined as detection of the same HPV type in 2 consecutive samples over a minimum of 150 days and 300 days, respectively; ASCUS+ was defined as ASCUS, low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells/high-grade ASCUS, does not exclude high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells of undetermined significance (AGUS), or HSIL. CIN1+ was defined as CIN1, CIN2, CIN3, adenocarcinoma in situ, or invasive cervical malignancy; CIN2+ excluded CIN1. Confounders (exposure variables) retained for the multivariable analysis were marital status, tobacco exposure (quantity of pack-years), age at first sexual intercourse, quantity of sexual partners prior to the past 12 months (ASCUS+, CIN1+, CIN2+), quantity of sexual partners during the past 12 months (event Fraxinellone and prolonged infections), at least 1 earlier pregnancy, sexually transmitted infection history, and region. Linear tendency was evaluated across 5 classes: (1) seronegative; (2) 1st quartile; (3) second quartile; (4) third quartile; (5) fourth quartile. Abbreviations: ASCUS, atypical squamous cell of undetermined significance; CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human being papillomavirus; PY, patient-years. a No. of instances and noncases and patient-years reported for the univariate analysis. Open in a separate window Open in a separate window Number 2. Cumulative probability of detecting an event or 6-month prolonged illness or developing atypical squamous cells of undetermined significance or higher (ASCUS+) associated with human being papillomavirus type 16 (HPV-16). and 3Valuevalue for linear tendency = .22New HPV-18 six-mo prolonged infection (instances = 297, noncases = 7685)aSeronegative272684826 4261.031.001.00Seropositive2583732020.780.76 (.50C1.14)0.86 (.56C1.30).46Seropositive, quartiles, EU/mL?7C1082358870.900.88 (.43C1.77)1.09 (.54C2.21).80?>10C1771927560.930.90 (.43C1.91)0.94 (.44C2.01).88?>17C4362047800.770.75 (.33C1.68)0.81 (.36C1.83).61?>43C108642067790.510.50 (.19C1.34)0.56 (.21C1.51).25value for linear tendency = Fraxinellone .17New HPV-18 twelve-mo prolonged infection (instances = 147, noncases = 7724)aSeronegative137688926 5920.521.001.00Seropositive1083532100.310.60 (.32C1.15)0.66 (.34C1.26).21Seropositive, quartiles, EU/mL?7C1022358940.220.43 (.11C1.75)0.56 (.14C2.26).41?>10C1731937560.400.77 (.25C2.42)0.79 (.25C2.49).69?>17C4322067860.250.49 (.12C2.00)0.52 (.13C2.13).37?>43C108632017740.390.75 (.24C2.36)0.75 (.23C2.39).63value for linear tendency = .68New ASCUS+ associated with HPV-18 (instances = 338, noncases = 7745)aSeronegative316689226 5711.191.001.00Seropositive2285332220.680.57 (.37C.88)0.64 (.41C.99).043Seropositive, quartiles, EU/mL?7C1072378920.790.66 (.31C1.40)0.81 (.38C1.72).58?>10C1751957560.660.56 (.23C1.34)0.60 (.25C1.46).26?>17C4342097890.510.43 (.16C1.14)0.46 (.17C1.25).13?>43C108662127860.760.64 (.29C1.44)0.67 (.29C1.51).33value for linear tendency = .17New CIN1+ associated with HPV-18 (instances = 67, noncases = 8016)aSeronegative66714227 0260.241.001.00Seropositive187432660.030.13 (.02C.90)0.13 (.02C.94).043Seropositive, quartiles, EU/mL?7C1002449040.00NDNDND?>10C1702007690.00NDNDND?>17C4302137960.00NDNDND?>43C108612177970.130.51 (.07C3.70)NDNDNew CIN2+ associated with HPV-18 (instances = 34, noncases = 8049)aSeronegative34717427 0620.131.00NDNDSeropositive087532670.00NDNDNDSeropositive, quartiles, EU/mL?7C1002449040.00NDNDND?>10C1702007690.00NDNDND?>17C4302137960.00NDNDND?>43C108602187980.00NDNDND Open in a separate window Event infection was defined as a new detection of the HPV type at any time during the follow-up period; 6- and 12-month prolonged infection were defined as detection of the same HPV type in 2 consecutive samples over a minimum of 150 days and 300 days, respectively; ASCUS+ was defined as ASCUS, low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells/high-grade ASCUS, does not exclude high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells of undetermined significance (AGUS), or HSIL. CIN1+ was defined as CIN1, CIN2, CIN3, adenocarcinoma in situ, or invasive cervical malignancy; CIN2+ excluded CIN1. Confounders (exposure variables) retained for the multivariable analysis were marital status, tobacco exposure (quantity of pack-years), age at first sexual intercourse, quantity of sexual partners prior to the past 12 months (ASCUS+, CIN1+, CIN2+), quantity of sexual partners during the past 12 months Fraxinellone (incident.